Date:7/9/2008

including those relating to future product development. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: unforeseen development and manufacturing problems; our ability to successfully obtain regulatory approvals and introduce new products in the clinical market; the performance and market acceptance of new products; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

CONTACTS:

For Media For Cepheid Investor

Inquiries: Inquiries:

Jared Tipton Jacquie Ross

Cepheid Corporate Cepheid Investor

Communications Relations

408-400-8377 408-400-8329

jared.tipton@cepheid.com jacquie.ross@cepheid.com

'/>"/>

SOURCE Cepheid Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3
Related biology technology :

1. McKool Smith Adds Noted Litigator in New York
2. Life Sciences Industry Reaches Crossroad Say Noted Pillsbury Attorneys
3. Industry Veterans Join Molecular Imprints Management Team
4. New molecular imaging techniques may lead to advances in disease treatment
5. Michigan Tech scientist models molecular switch
6. 3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
7. Molecular changes in brain fluid give insight into brain-damaging disease
8. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
9. Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics
10. Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16
11. Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay